8-K: Terns Pharma Upsizes Public Offering to $650M

Terns Pharmaceuticals announced the pricing of an upsized underwritten public offering of common stock, expected to generate approximately $705.8 million in net proceeds to fund its pipeline and extend its cash runway into 2031.

Summary

• Terns Pharmaceuticals, Inc. priced an upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share.
• The underwriters fully exercised their 30-day option to purchase an additional 2,437,500 shares of common stock, bringing the total shares offered to 18,687,500.
• The gross proceeds from the offering are expected to be approximately $747.5 million (including the full exercise of the option).
• The estimated net proceeds from the offering are approximately $705.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.
• The offering is expected to close on December 11, 2025.
• The company estimates that its existing cash, cash equivalents, marketable securities, and the net proceeds from this offering will be sufficient to fund its operating expenses and capital expenditure requirements at least into 2031.

Sentiment

Score: 8

Explanation: The successful pricing of an upsized public offering, coupled with the full exercise of the underwriters' option, demonstrates strong market confidence. The substantial net proceeds significantly extend the company's cash runway, providing critical funding for advancing its clinical pipeline, particularly TERN-701, and supporting future commercialization efforts. While dilution is a factor, the long-term financial stability and ability to progress key programs are highly positive for a clinical-stage biotech.

Positives

• Successful pricing of an upsized public offering, indicating strong investor demand and confidence.
• Significant capital raise of approximately $705.8 million in net proceeds, substantially bolstering the company's financial position.
• Extension of the company's cash runway at least into 2031, providing long-term financial stability for critical research and development activities.
• Funding is allocated to advance key product candidates, including TERN-701, through research, clinical trials, development, and manufacturing.
• Proceeds will also support initial activities for the potential future commercial launch of TERN-701.

Negatives

• The issuance of 18,687,500 new shares of common stock will result in significant dilution for existing shareholders.
• The offering price of $40.00 per share may be below recent trading prices, potentially impacting shareholder value in the short term.

Risks

• The anticipated net proceeds from the offering, the anticipated closing, and the sufficiency of the company's cash resources are forward-looking statements and subject to inherent risks and uncertainties.
• The company's estimate for its cash runway into 2031 is based on assumptions that may prove incorrect, potentially leading to available capital being used sooner than expected.
• Risks are associated with the satisfaction of customary closing conditions related to the offering, which could prevent its completion.
• The initiation, cost, timing, progress, results, and utility of the company's current and future research and development activities, preclinical studies, and clinical trials are subject to significant risks.
• General risk factors identified in the company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, could materially affect the company's plans and financial condition.

Future Outlook

The company intends to use the net proceeds from the offering to fund research, clinical trials, development, and manufacturing of key product candidates, including TERN-701. It also plans for initial activities in preparation for the potential future commercial launch of TERN-701 and for working capital and general corporate purposes. This capital raise is expected to extend the company's cash runway at least into 2031, providing a long-term financial horizon for its operations.

Management Comments

• Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering.
• Terns intends to use the net proceeds from the proposed offering to fund research, clinical trials, development and manufacturing of key product candidates, including TERN-701, initial activities in preparation for the potential future commercial launch of TERN-701 and for working capital and general corporate purposes.
• Based on current plans, the Company estimates that its existing cash, cash equivalents and marketable securities, together with the estimated net proceeds from the Offering, will be sufficient to enable the Company to fund its operating expenses and capital expenditure requirements at least into 2031.

Industry Context

Terns Pharmaceuticals is a clinical-stage oncology company, a sector characterized by high research and development costs and a long, uncertain path to market for new drugs. This significant capital raise is a common and necessary strategy for such companies to finance their extensive drug pipelines. The funding specifically targets TERN-701, an allosteric BCR-ABL inhibitor, which aims to improve treatments for Chronic Myeloid Leukemia (CML), highlighting the company's focus within the competitive oncology therapeutic area.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares but benefit from the company's significantly extended cash runway and enhanced ability to fund its pipeline, potentially increasing long-term value.
• Employees will benefit from increased job security and continued opportunities for research and development as the company's financial stability is strengthened.
• Customers and patients could potentially benefit from the accelerated development and eventual commercialization of TERN-701 and other product candidates, offering new treatment options.
• Creditors will see improved financial stability and liquidity, which reduces the company's credit risk.

Next Steps

• The closing of the offering is expected to take place on December 11, 2025.
• Proceeds will be used to fund research, clinical trials, development, and manufacturing of key product candidates, including TERN-701.
• Initial activities in preparation for the potential future commercial launch of TERN-701 will be undertaken.
• The company will continue to fund its operating expenses and capital expenditure requirements, with sufficient capital estimated at least into 2031.

Key Dates

Recommendation

This filing details a significant capital raise that provides Terns Pharmaceuticals with substantial funding and extends its cash runway for several years. For a clinical-stage oncology company, securing such financing is crucial for advancing its pipeline, particularly the lead candidate TERN-701. While the offering results in dilution for existing shareholders, the enhanced financial stability and ability to execute on strategic development plans are positive. However, as this is a financing event rather than a clinical or operational update, and given the inherent risks of a clinical-stage biotech, a 'hold' recommendation is appropriate, awaiting further clinical milestones and data before a stronger directional call.

Keywords

Terns Pharmaceuticals, TERN, Public Offering, Equity Offering, Capital Raise, Oncology, Clinical-stage, TERN-701, BCR-ABL inhibitor, Cash Runway, Biotechnology, Pharmaceuticals, SEC Filing, Form 8-K